International Drug Pricing, Trade Policy & Commercialization

Lanton Strategies International advises pharmaceutical and biotechnology companies on the effects of international drug pricing, trade policy and regulatory developments on commercial decisions across the United States, European Union and United Kingdom.

International drug pricing and launch sequencing

We assess how international reference pricing, most-favored-nation (MFN) policies and government reimbursement decisions can affect launch timing, market access and revenue strategy across markets.

Trade policy and pharmaceutical supply chains

We examine the commercial implications of tariffs, trade negotiations, sourcing requirements and cross-border policy developments. Our advisory work helps executives evaluate exposure, identify strategic options and prepare for changing market conditions.

Transatlantic commercialization strategy

We help leadership teams connect policy developments with market entry, distribution, partnerships and product commercialization decisions. Our analysis supports board discussions, scenario planning and government engagement priorities.

Explore our pharmaceutical pricing and market access advisory, U.S. market entry services or contact LSI to discuss your international strategy.